Keele Research Repository

Article

Wheatley, D, Haviland, J, Patel, J, Sydenham, M, Alhasso, A, Chan, C, Cleator, S, Coles, C, Donovan, E, Kirby, A, Kirwan, C, Nabi, Z, Sawyer, E, Somaiah, N, Syndikus, I, Venables, K, Yarnold, J, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097 and Bliss, J (2022) First results of FAST-Forward phase 3 RCT nodal substudy: 3-year normal tissue effects. Radiotherapy and Oncology, 170. S75 - S76.

Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Haviland, JS, Wheatley, DA, Sydenham, MA, Alhasso, A, Bloomfield, D, Chan, C, Churn, M, Cleator, S, Coles, CE, Emson, M, Goodman, A, Harnett, A, Hopwood, P, Kirby, AM, Kirwan, C, Morris, C, Nabi, Z, Sawyer, E, Somaiah, N, Stones, L, Syndikus, I, Wilcox, M, Bliss, JM and Yarnold, JR (2020) FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 5-year results. Radiotherapy and Oncology, 152 (S1). S346 - S347.

Brunt, AM, Haviland, JS, Wheatley, DA, Sydenham, MA, Alhasso, A, Bloomfield, DJ, Chan, C, Churn, M, Cleator, S, Coles, CE, Goodman, A, Harnett, A, Hopwood, P, Kirby, AM, Kirwan, CC, Morris, C, Nabi, Z, Sawyer, E, Somaiah, N, Stones, L, Syndikus, I, Bliss, JM, Yarnold, JR and FAST-Forward Trial Management Group, . (2020) Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. The Lancet, 395 (10237). 1613 - 1626.

Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Haviland, J, Sydenham, M, Alhasso, A, Bloomfield, D, Chan, C, Churn, M, Cleator, S, Coles, C, Emson, M, Goodman, A, Griffin, C, Harnett, A, Hopwood, P, Kirby, A, Kirwan, C, Morris, C, Sawyer, E, Somaiah, N, Syndikus, I, Wilcox, M, Rada, Z, Wheatley, D, Bliss, J and Yarnold, J (2018) FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 3-year normal tissue effects. British Journal of Cancer, 119 (11). 41 - 41.

Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Haviland, J, Sydenham, M, Al-hasso, A, Bloomfield, D, Chan, C, Churn, M, Cleator, S, Coles, C, Emson, M, Goodman, A, Griffin, C, Harnett, A, Hopwood, P, Kirby, A, Kirwan, C, Morris, C, Sawyer, E, Somaiah, N, Syndikus, I, Wilcox, M, Zotova, R, Wheatley, D, Bliss, J and Yarnold, J (2018) FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 3-year normal tissue effects. Radiotherapy and Oncology, 127 (S1). S311 -S312.

Coles, C, Griffin, C, Kirby, A, Agrawal, R, Alhasso, A, Bhattacharya, I, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Ciurlionis, L, Chan, H, Donovan, E, Emson, M, Harnett, A, Haviland, J, Hopwood, P, Jefford, M, Kaggwa, R, Sawyer, E, Sybdikus, I, Tsang, Y, Wheatley, D, Wilcox, M, Yarnold, J and Bliss, J (2017) Partial breast radiotherapy after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology, 123 (S1). S162 -S163.

Conference or Workshop Item

Coles, C, Haviland, JS, Kirby, AM, Bhattacharya, I, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Chan, C, Donovan, EM, Eaton, DJ, Griffin, CL, Hopwood, P, Jefford, ML, Lightowlers, S, Rajapakse, C, Sawyer, E, Stones, L, Syndikus, I, Titley, JC, Tsang, Y, Twyman, NI, Bliss, JM and Yarnold, JR (2021) IMPORT HIGH trial: Dose escalated simultaneous integrated boost radiotherapy in early breast cancer. In: ESTRO 2021, 28-31 August 2021, Madrid, Spain & Online.